It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Fluorizoline is a prohibitin-binding compound that triggers apoptosis in several cell lines from murine and human origin, as well as in primary cells from hematologic malignancies by inducing the integrated stress response and ER stress. Recently, it was described that PHB (Prohibitin) 1 and 2 are crucial mitophagy receptors involved in mediating the autophagic degradation of mitochondria. We measured mitophagy in HeLa cells expressing Parkin and in A549, a lung cancer cell line that can undergo mitophagy in a Parkin-independent manner, and we demonstrated that both fluorizoline and rocaglamide A, another PHB-binding molecule, inhibit CCCP- and OA-induced mitophagy. Moreover, we demonstrated that PHBs are mediating Parkin-dependent mitophagy. In conclusion, besides being a potent pro-apoptotic compound, we present fluorizoline as a promising new mitophagy modulator that could be used as anticancer agent.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Iglesias-Serret, Daniel 4 ; Marchetti Sandrine 3 ; Gil, Joan 2
1 Universitat de Barcelona, Oncobell-IDIBELL (Institut d’Investigació Biomèdica de Bellvitge), L’Hospitalet de Llobregat, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Université Côte d’Azur, INSERM, Nice, France (GRID:grid.460782.f) (ISNI:0000 0004 4910 6551); Equipe labellisée Ligue Contre le Cancer, Nice, France (GRID:grid.460782.f)
2 Universitat de Barcelona, Oncobell-IDIBELL (Institut d’Investigació Biomèdica de Bellvitge), L’Hospitalet de Llobregat, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
3 Université Côte d’Azur, INSERM, Nice, France (GRID:grid.460782.f) (ISNI:0000 0004 4910 6551); Equipe labellisée Ligue Contre le Cancer, Nice, France (GRID:grid.460782.f)
4 Universitat de Barcelona, Oncobell-IDIBELL (Institut d’Investigació Biomèdica de Bellvitge), L’Hospitalet de Llobregat, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Universitat de Vic–Universitat Central de Catalunya (UVic- UCC), Vic, Facultat de Medicina, Barcelona, Spain (GRID:grid.440820.a)




